Last reviewed · How we verify

IRCCS San Raffaele Roma — Portfolio Competitive Intelligence Brief

IRCCS San Raffaele Roma pipeline: 2 marketed, 0 filed, 0 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 5 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Levodopa Benserazide Teva Italia Levodopa Benserazide Teva Italia marketed Dopamine precursor with peripheral decarboxylase inhibitor Aromatic amino acid decarboxylase (inhibited by benserazide); dopamine receptors (target of levodopa-derived dopamine) Neurology
Levodopa Benserazide Madopar Levodopa Benserazide Madopar marketed Dopamine precursor with peripheral decarboxylase inhibitor Dopamine pathway; aromatic amino acid decarboxylase (inhibited by benserazide) Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie · 1 shared drug class
  2. Bial - Portela C S.A. · 1 shared drug class
  3. Intec Pharma Ltd. · 1 shared drug class
  4. NeuroDerm Ltd. · 1 shared drug class
  5. Pfizer · 1 shared drug class
  6. Ross D. Zafonte, MD · 1 shared drug class
  7. University of Buenos Aires · 1 shared drug class
  8. XenoPort, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for IRCCS San Raffaele Roma:

Cite this brief

Drug Landscape (2026). IRCCS San Raffaele Roma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/irccs-san-raffaele-roma. Accessed 2026-05-16.

Related